No change in the pharmacokinetics of lopinavir. No dose adjustment necessary.

Drug interaction studies revealed no clinically significant interaction between lopinavir and lamivudine.

Lamivudine metabolism does not involve CYP3A, making interactions with medicinal products metabolised by this system (e.g. PIs) unlikely.

Plasma concentrations of lamivudine (300 mg once daily) with lopinavir/ritonavir (400/100 mg twice daily, n=7) or nevirapine (400 mg once daily, n=8) were determined in HIV positive patients. Lamivudine AUC, Cmax and Ctrough were 11%, 21% and 45% higher, respectively in the presence of lopinavir/ritonavir when compared to nevirapine. The changes in lamivudine disposition were not significant.